North America Sickle Cell Disease Market Trends, Growth, Demand, opportunities, Scope & Forecast period
Sickle cell disease (SCD) is a series of inherited red blood cell abnormalities in which an individual's red blood cells become sticky and practically "C" or curved in shape, hence the name "sickle cell disease." Sickle cell anemia, sickle cell beta-thalassemia, sickle Hemoglobin C Disease, and other sickle cell disorders are among them. Anemia, periods of discomfort, swelling of the hands and feet, and other symptoms are all connected with sickle cell disease.
gastrointestinal
effects such as gastric distress, gastritis, mucositis, and oral mucosa ulcer,
dermatological effects such as painful skin ulcers, aphthous ulcers,
non-ulcerative toxicity with erythema, and skin infiltration, and it can also
decrease sperm count and motility in males are all major side effects of
hydroxyurea on long-term treatment in sickle cell disease patients. Medications
and blood transfusions are used to treat sickle cell disease. A stem cell transplant may be able to treat the condition in certain children and teenagers.
Over the
projected period, the North American sickle cell disease market is expected to
rise due to an increase in product approvals by key companies for the treatment
of sickle cell disease. For example, in May 2021, Chiesi Farmaceutici S.p.A., a the pharmaceutical company announced that FERRIPROX (deferiprone) had been
approved by the US Food and Drug Administration for the treatment of
transfusional iron overload due to sickle cell disease (SCD) and anemia in
pediatric and adult patients aged three years and older.
The North
America sickle cell disease market is projected to be hampered by major
adverse effects of pharmacological treatments such as hydroxyurea. According to
a report published by Starpearls, an authenticated healthcare library around
the world, and articles reviewed by PubMed (MEDLINE database of references and
abstracts on life sciences and biomedical topics), hydroxyurea has
gastrointestinal, dermatological, and reptilian side effects on long-term
treatment in sickle cell disease patients.
Novartis
International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood
Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo
Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi
Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc. are among
the major players in the North American

Comments
Post a Comment